2. Academic Validation
  3. Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges

Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges

  • Bioorg Med Chem Lett. 2019 Jul 1;29(13):1555-1564. doi: 10.1016/j.bmcl.2019.04.030.
Scott D Edmondson 1,  Bin Yang 2,  Charlene Fallan 3
Affiliations

Affiliations

  • 1 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA, USA. Electronic address: scott.edmondson@astrazeneca.com.
  • 2 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, MA, USA.
  • 3 Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
PMID: 31047748 DOI: 10.1016/j.bmcl.2019.04.030
Abstract

Proteolysis targeting chimeras (PROTACs) are heterobifunctional compounds with molecular weights and Other properties that lie outside the classic 'rule-of-five' space. Consequently, PROTACs have unique challenges associated with their development as potential therapeutic agents. This review summarizes and analyzes a representative set of recent PROTACs and highlights some of the potential future challenges facing this promising modality.

Keywords

Absorption; Beyond rule-of-five; Degradation; Oral bioavailability; PROTACs; Proteolysis targeting chimeras; bRo5.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z